At the news
? NEUTRALIMPACT 3/10 8-K filed Jul 14, 2026 at 17:00 ET
Anika Therapeutics entered into a Fifth Amendment to its existing credit agreement with Bank of America on July 10, 2026, reducing the revolving facility to $50 million and extending the maturity to July 10, 2031. The amendment includes a potential $50 million accordion feature, SOFR-based pricing with a spread of 0.25%-1.25%, and financial covenants (max leverage 3.50x, min interest coverage 3.00x). This is a routine refinancing that provides extended liquidity without material new financial data.
- Revolving credit facility reduced to $50 million (from an undisclosed prior amount) with a maturity date of July 10, 2031.
- Company may request up to an additional $50 million in commitments, subject to lender approval, for a maximum of $100 million.
- Interest rate is SOFR plus 0.25% to 1.25% based on consolidated leverage ratio; commitment fee is 0.20% to 0.30% per annum.
- Financial covenants: maximum Consolidated Net Leverage Ratio of 3.50x (stepping to 4.00x for material acquisitions) and minimum Consolidated Interest Coverage Ratio of 3.00x.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access